Cyrus L. Harmon
Olema Pharmaceuticals (United States)(US)
Publications by Year
Research Areas
Estrogen and related hormone effects, Advanced Breast Cancer Therapies, Computational Drug Discovery Methods, HER2/EGFR in Cancer Research, Advanced Data Storage Technologies
Most-Cited Works
- → A 1.1-Mb Transcript Map of the Hereditary Hemochromatosis Locus(1997)83 cited
- → Specific stereochemistry of OP-1074 disrupts estrogen receptor alpha helix 12 and confers pure antiestrogenic activity(2018)64 cited
- → Palazestrant (OP-1250), A Complete Estrogen Receptor Antagonist, Inhibits Wild-type and Mutant ER-positive Breast Cancer Models as Monotherapy and in Combination(2023)33 cited
- → Genoviz Software Development Kit: Java tool kit for building genomics visualization applications(2009)29 cited
- → Abstract P1-17-12: Preliminary data from a phase I/II, multicenter, dose escalation study of OP-1250, an oral CERAN/SERD, in subjects with advanced and/or metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer(2022)19 cited
- → Comparative Analysis of Spatial Patterns of Gene Expression in Drosophila melanogaster Imaginal Discs(2007)11 cited
- → Joint Nonparametric Alignment for Analyzing Spatial Gene Expression Patterns in Drosophila Imaginal Discs(2005)10 cited
- → OP-1250: A potent orally available complete antagonist of estrogen receptor-mediated signaling that shrinks wild type and mutant breast tumors(2020)7 cited
- → Abstract 4376: OP-1250, a complete estrogen receptor antagonist (CERAN) that shrinks estrogen receptor positive tumors and exhibits favorable pharmacokinetics(2020)6 cited
- → Abstract LB122: The complete estrogen receptor antagonist (CERAN) OP-1250 shrinks ER+ brain metastases in an intracranial xenograft tumor model expressing mutant ESR1(2021)4 cited